- Home
- EWCZ vs ZNTL Comparison
EWCZ vs ZNTL Comparison
Compare EWCZ & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EWCZ | ZNTL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 257.5M | 289.0M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | EWCZ | ZNTL |
|---|---|---|
| Price | $5.83 | $3.62 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $5.87 | ★ $6.60 |
| AVG Volume (30 Days) | ★ 5.6M | 952.1K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.76 | N/A |
| Revenue Next Year | $2.29 | N/A |
| P/E Ratio | $21.96 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.25 | $1.13 |
| 52 Week High | $6.52 | $6.95 |
Technical Indicators
Market Signals| Indicator | EWCZ | ZNTL |
|---|---|---|
| Relative Strength Index (RSI) | 60.73 | 41.94 |
| Support Level | $3.53 | $1.34 |
| Resistance Level | $5.90 | $4.38 |
| Average True Range (ATR) | 0.02 | 0.29 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 50.00 | 18.13 |
Price Performance
Historical ComparisonAbout EWCZ European Wax Center Inc.
European Wax Center Inc is a franchisor and operator of OOH waxing services. Its product sales consist of revenue earned from sales of proprietary wax. Its services include Brazilian Waxing, Brow Waxing, Body Waxing, Facial Waxing, All Waxing Services, Eyebrow Tinting, Laser Hair Removal, Men's Waxing Services, and others.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.